Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

OOTC:ACUR
0.00
USD
0.00
(0.00%)
-0.02EPS
32.55MMarket Cap

Total Valuation

USD

As of December 31, 2021, Acura Pharmaceuticals, Inc. carries a market capitalization of 32.55M, placing it among publicly traded companies globally. Its enterprise value stands at 32.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap32.55M
Enterprise Value32.68M

Share Statistics

As of December 31, 2021, Acura Pharmaceuticals, Inc. has 65.09M shares outstanding.

Shares Outstanding65.09M

Valuation Ratios

These figures are as of December 31, 2021. The price-to-sales ratio is 18.12, and the price-to-book ratio stands at 182.85.

PS Ratio18.12
PB Ratio182.85
P/TBV Ratio182.85
P/FCF Ratio-38.16
P/OCF Ratio-38.16

Enterprise Valuation

These figures are as of December 31, 2021. The EV/Sales ratio of 20.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 32.68M versus a market cap of 32.55M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales20.91

Financial Position

As of December 31, 2021, Acura Pharmaceuticals, Inc. maintains a current ratio of 0.72, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 112.36, indicating elevated leverage, while an interest coverage ratio of -5.62 demonstrates limited ability to service its debt obligations.

Current Ratio0.72
Quick Ratio0.43
Debt / Equity112.36
Debt / EBITDA-0.18
Interest Coverage-5.62

Financial Efficiency

USD

These figures cover the twelve months ended December 31, 2021. Return on assets (ROA) is negative at -67.72, reflecting losses generated across the asset base. The company generates approximately 130,250.00 in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-67.72
Revenue Per Employee130,250.00
Employee Count12.00

Stock Price Statistics

As of the close on November 16, 2026, Acura Pharmaceuticals, Inc.'s stock has declined approximately 25.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

52-Week Price Change-25.00%

Income Statement

USD

Over the twelve months ended December 31, 2021, Acura Pharmaceuticals, Inc. generated 1.56M in revenue and converted that into -879,000.00 in net income, yielding earnings per share of -0.02. EBITDA reached -1.12M, while operating income came in at -1.21M.

Revenue1.56M
Operating Income-1.21M
Pretax Income-879,000.00
Net Income-879,000.00
EBITDA-1.12M
EBIT-1.21M
Earnings Per Share (EPS)-0.02

Balance Sheet

USD

As of December 31, 2021, Acura Pharmaceuticals, Inc. holds 65,000.00 in cash and equivalents against 200,000.00 in total debt, resulting in a net debt position of 85,000.00. Total book value stands at 178,000.00, with working capital of -143,000.00 providing operational flexibility.

Cash & Cash Equivalents65,000.00
Total Debt200,000.00
Net Debt85,000.00
Equity (Book Value)178,000.00
Working Capital-143,000.00

Cash Flow

USD

Acura Pharmaceuticals, Inc. produced -742,000.00 in operating cash flow over the twelve months ended December 31, 2021.

Operating Cash Flow-742,000.00
Free Cash Flow-742,000.00
FCF Per Share-0.01

Margins

These figures cover the twelve months ended December 31, 2021. The operating margin of -77.67 and net profit margin of -56.24 provide insight into operational efficiency.

Operating Margin-77.67
Pretax Margin-56.24
Profit Margin-56.24
EBITDA Margin-71.91

Dividends & Yields

These figures cover the twelve months ended December 31, 2021. Free cash flow yield is negative at -2.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.21, meaning Acura Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-1.21
FCF Yield-2.62

Stock Splits

Acura Pharmaceuticals, Inc.'s most recent stock split took place on August 28, 2015 with a 5:1 split ratio.

Last Split Date8/28/2015
Split Ratio5:1

Scores

As of December 31, 2021, Acura Pharmaceuticals, Inc. has an Altman Z-Score of -609.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-609.43